The approval for the generic version of Lanreotide Acetate is in line with Cipla’s growth strategy in the complex product segment and will strengthen Cipla’s position in the US market.
 "Cipla rallies 4% on US FDA approval to market Lanreotide injection")
SI Reporter Mumbai
The surge came after the company said that it has received a final approval from the United States Food and Drugs Administration (US FDA) for lanreotide injection.
The approval for the generic version of Lanreotide Acetate is in line with Cipla’s growth strategy in the complex product segment and will strengthen Cipla’s position in the US market.
Click here to follow our WhatsApp channel
Cipla USA Inc., wholly owned subsidiary of the Company in USA has received the final approval for its Abbreviated New Drug Application (ANDA) for Lanreotide Injection 120 mg/0.5 mL, 90 mg/0.3 mL, 60 mg/0.2 mL from USFDA, Cipla said in exchange filing.
Cipla’s Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline® Depot (lanreotide) Injection and is indicated for the treatment of patients with Acromegaly and Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs), the company said.
According to IQVIA (IMS Health), Somatuline® Depot (Lanreotide) had US sales of approximately $898 million for the 12-month period ending March 2024.
At 01:55 PM, Cipla stock was trading 3.4 per cent higher at Rs 1,492.30, as compared…
